Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review

Kathleen M. Capaccione, Jacienta P. Valiplackal, Alice Huang, Tina Roa, Alana Fruauff, Connie Liou, Eleanor Kim, Sakshi Khurana, Mary Maher, Hong Ma, Pamela Ngyuen, Serena Mak, Shifali Dumeer, Sonali Lala, Belinda D'souza, Sherelle Laifer-Narin, Elise Desperito, Carrie Ruzal-Shapiro, Mary M. Salvatore

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Cancer immunotherapies are drugs that modulate the body's own immune system as an anticancer strategy. Checkpoint inhibitor immunotherapies interfere with cell surface binding proteins that function to promote self-recognition and tolerance, ultimately leading to upregulation of the immune response. Given the striking success of these agents in early trials in melanoma and lung cancer, they have now been studied in many types of cancer and have become a pillar of anticancer therapy for many tumor types. However, abundant upregulation results in a new class of side effects, known as immune-related adverse events (IRAEs). It is critical for the practicing radiologist to be able to recognize these events to best contribute to care for patients on checkpoint inhibitor immunotherapy. Here, we provide a comprehensive system-based review of immune-related adverse events and associated imaging findings. Further, we detail the best imaging modalities for each as well as describe problem solving modalities. Given that IRAEs can be subclinical before becoming clinically apparent, radiologists may be the first provider to recognize them, providing an opportunity for early treatment. Awareness of IRAEs and how to best image them will prepare radiologists to make a meaningful contribution to patient care as part of the clinical team.

Original languageEnglish
Pages (from-to)1869-1884
Number of pages16
JournalAcademic Radiology
Issue number12
StatePublished - Dec 2022
Externally publishedYes


  • Checkpoint inhibitor
  • IRAE
  • Immune-related adverse events
  • Immunotherapy


Dive into the research topics of 'Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review'. Together they form a unique fingerprint.

Cite this